Dexcom Inc. revealed new clinical data at the European Association for the Study of Diabetes (EASD) which highlighted the benefits of the use of continuous glucose monitoring (CGM). Results from the COMISAIR seven-year study, the longest prospective real-world CGM trial ever conducted, showed significant and continued reduction of HbA1c with the use of real-time CGM by people with type 1 diabetes.
The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany. Making its debut at this prestigious event, Shenzhen Sibionics Technology Co., Ltd. (hereinafter referred to as "SIBIONICS") will unveil its flagship product, the SIBIONICS GS1 Continuous Glucose Monitoring System (hereinafter referred to as "SIBIONICS GS1 CGM"), while also sharing its wealth of expertise and cutting-edge glucose monitoring
The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany. Making its debut at this prestigious event, Shenzhen Sibionics Technology Co., Ltd. (hereinafter referred to as "SIBIONICS") will unveil its flagship product, the SIBIONICS GS1 Continuous Glucose Monitoring System (hereinafter referred to as "SIBIONICS GS1 CGM"), while also sharing its wealth of expertise and cutting-edge glucose monitoring
Do you or someone you know living with Type 2 Diabetes (T2D) consider the fact that a world in which innovation is constant and technology can be used to make life better for people with this condition?There has been significant progress in the field of T2D. This article discusses exciting developments in glucose management that